Search

Brian A. Whiteman

Examiner (ID: 15660, Phone: (571)272-0764 , Office: P/1674 )

Most Active Art Unit
1635
Art Unit(s)
1674, 1636, 1633, 1635
Total Applications
1778
Issued Applications
936
Pending Applications
245
Abandoned Applications
622

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 14182739 [patent_doc_number] => 20190111074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA [patent_app_type] => utility [patent_app_number] => 16/192661 [patent_app_country] => US [patent_app_date] => 2018-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16192661 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/192661
TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA Nov 14, 2018 Abandoned
Array ( [id] => 14210823 [patent_doc_number] => 20190117796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA [patent_app_type] => utility [patent_app_number] => 16/192622 [patent_app_country] => US [patent_app_date] => 2018-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16192622 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/192622
TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA Nov 14, 2018 Abandoned
Array ( [id] => 18590442 [patent_doc_number] => 11739326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition [patent_app_type] => utility [patent_app_number] => 16/763880 [patent_app_country] => US [patent_app_date] => 2018-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 91 [patent_no_of_words] => 27572 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763880 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/763880
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition Nov 13, 2018 Issued
Array ( [id] => 17938645 [patent_doc_number] => 11473089 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Aptamer for ADAMTS5 and use for aptamer for ADAMTS5 [patent_app_type] => utility [patent_app_number] => 16/761880 [patent_app_country] => US [patent_app_date] => 2018-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 20018 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761880 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/761880
Aptamer for ADAMTS5 and use for aptamer for ADAMTS5 Nov 8, 2018 Issued
Array ( [id] => 19256315 [patent_doc_number] => 12016339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Control of plant pests using RNA molecules [patent_app_type] => utility [patent_app_number] => 16/756232 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32167 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756232 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/756232
Control of plant pests using RNA molecules Nov 5, 2018 Issued
Array ( [id] => 16206901 [patent_doc_number] => 20200239891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => CONTROL OF PLANT PESTS USING RNA MOLECULES [patent_app_type] => utility [patent_app_number] => 16/756298 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756298 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/756298
Control of plant pests using RNA molecules Nov 5, 2018 Issued
Array ( [id] => 16437093 [patent_doc_number] => 20200354419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/761112 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761112 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/761112
COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Nov 1, 2018 Abandoned
Array ( [id] => 16598369 [patent_doc_number] => 20210024900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION [patent_app_type] => utility [patent_app_number] => 16/761009 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761009 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/761009
METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION Nov 1, 2018 Abandoned
Array ( [id] => 16028677 [patent_doc_number] => 10676747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Methods for improving cognitive function via modulation of quinone reductase 2 [patent_app_type] => utility [patent_app_number] => 16/173959 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 25 [patent_no_of_words] => 14218 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16173959 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/173959
Methods for improving cognitive function via modulation of quinone reductase 2 Oct 28, 2018 Issued
Array ( [id] => 16704598 [patent_doc_number] => 10954519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression [patent_app_type] => utility [patent_app_number] => 16/167783 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44943 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16167783 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/167783
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression Oct 22, 2018 Issued
Array ( [id] => 18558763 [patent_doc_number] => 11723988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector [patent_app_type] => utility [patent_app_number] => 16/756988 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14761 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756988 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/756988
Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector Oct 21, 2018 Issued
Array ( [id] => 15975737 [patent_doc_number] => 10668170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Modified RNAi agents [patent_app_type] => utility [patent_app_number] => 16/165343 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30835 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165343 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/165343
Modified RNAi agents Oct 18, 2018 Issued
Array ( [id] => 16703121 [patent_doc_number] => 10953034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection [patent_app_type] => utility [patent_app_number] => 16/162279 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 47475 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16162279 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/162279
Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection Oct 15, 2018 Issued
Array ( [id] => 13871441 [patent_doc_number] => 20190032061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions [patent_app_type] => utility [patent_app_number] => 16/157726 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16157726 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/157726
RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions Oct 10, 2018 Abandoned
Array ( [id] => 16244823 [patent_doc_number] => 10744151 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-08-18 [patent_title] => Micro-RNA profiling, compositions, and methods of treating diseases [patent_app_type] => utility [patent_app_number] => 16/153342 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 11185 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153342 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/153342
Micro-RNA profiling, compositions, and methods of treating diseases Oct 4, 2018 Issued
Array ( [id] => 16290342 [patent_doc_number] => 10767179 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => MicroRNA composition for the treatment of neuroblastoma [patent_app_type] => utility [patent_app_number] => 16/148466 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 11987 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148466 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/148466
MicroRNA composition for the treatment of neuroblastoma Sep 30, 2018 Issued
Array ( [id] => 14043975 [patent_doc_number] => 20190078094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => Aptamer specifically binding to L-Ascorbic acid and use of the same [patent_app_type] => utility [patent_app_number] => 16/148236 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148236 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/148236
Aptamer specifically binding to L-Ascorbic acid and use of the same Sep 30, 2018 Issued
Array ( [id] => 16223062 [patent_doc_number] => 20200248178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/649565 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649565 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/649565
COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY Sep 27, 2018 Abandoned
Array ( [id] => 16157235 [patent_doc_number] => 20200216850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => SPLICE INHIBITING OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/648822 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648822 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/648822
Splice inhibiting oligonucleotides Sep 20, 2018 Issued
Array ( [id] => 18701589 [patent_doc_number] => 11788088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => CRISPR/Cas system and method for genome editing and modulating transcription [patent_app_type] => utility [patent_app_number] => 16/650496 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 23 [patent_no_of_words] => 22359 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650496 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/650496
CRISPR/Cas system and method for genome editing and modulating transcription Sep 20, 2018 Issued
Menu